Worldwide more than eight million people die of cancer each year. The chance of survival depending on the type of cancer, the stage at which it is diagnosed and the speed with which appropriate treatment is launched. Skyline Diagnostics, a Dutch company associated with the Erasmus Medical Center in Rotterdam, has developed a unique diagnostic test for… Continue
Added by Peter Hofland, PhD on March 16, 2011 at 9:00pm —
For the first time, scientists in Syracuse University's Chemistry Department have created a new drug delivery system expected to advance the effectiveness of cancer-killing drugs. The delivery system uses gold nanoparticles with attached DNA that binds to Doxorubicin or DOX, an anthracycline antibiotic which is closely related to the natural p… Continue
Added by Peter Hofland, PhD on March 16, 2011 at 5:00am —
A cutting-edge scientific study reveals promising results for a prostate cancer vaccine. The nation’s most prestigious scientists and clinicians have joined together this week to reveal this and other groundbreaking discoveries at the Prostate Cancer Research Program’s (PCRP’s) Innovative Minds in Prostate Cancer Today (IMPaCT) conference in Orlando, Fla.
The Department of Defense Prostate Cancer Research… Continue
Added by Peter Hofland, PhD on March 10, 2011 at 12:30pm —
Research led by scientists at the St. Jude Children's Research Hospital, an internationally recognized for its pioneering research and treatment of children with cancer, helped identify the gene as a potential marker of relapse risk and involved the most comprehensive search yet for genomic changes in relapsed childhood acute lymphoblastic leukemia (ALL).
Despite dramatically improved survival rates for… Continue
Added by Peter Hofland, PhD on March 9, 2011 at 10:00am —
Whole genome sequencing, spelling out a person’s entire DNA genetic code, has moved one step closer to being a medical option for direct patient care. Physicians and researchers at Mayo Clinic in Arizona and the Translational Genomics Research Institute (TGen) successfully completed sequencing both a single patients normal and cancer cells, a tour de force of more than 6 billion… Continue
Added by Peter Hofland, PhD on February 16, 2011 at 6:30am —
For the first time, researchers from the Broad Institute, Dana-Farber Cancer Institute and Weill Cornell Medical College have have laid bare the full genetic blueprint of multiple prostate tumors, uncovering alterations that have never before been detected. The full blueprint offers a deep view of the genetic… Continue
Added by Peter Hofland, PhD on February 9, 2011 at 5:00pm —
The first genome-wide study to demonstrate an inherited genetic basis for racial and ethnic disparities in cancer survival linked Native American ancestry with an increased risk of relapse in young leukemia patients. The work was done by investigators at St. Jude Children's Research Hospital, internationally recognized for its pioneering research and treatment of children with cancer, and the Children's Oncology Group (COG). Continue
Along with identifying Native…
Added by Peter Hofland, PhD on February 6, 2011 at 10:00am —
For several decades, researchers have been linking genetic mutations to diseases ranging from cancer to developmental abnormalities. What hasn't been clear, however, is how the body's genome sustains such destructive glitches in the first place. Now a team of scientists and research collaborators at the Mayo Clinic provide an unprecedented glimpse of a little-understood gene, called MMSET, revealing how it enables… Continue
Added by Peter Hofland, PhD on February 2, 2011 at 5:30pm —
Researchers at Johns Hopkins have found a better way to create induced pluripotent stem (iPS) cells—adult cells reprogrammed with the properties of embryonic stem cells—from a small blood sample. This new method, described last week in Cell Research, avoids creating DNA changes that could lead to… Continue
Added by Peter Hofland, PhD on January 31, 2011 at 5:00pm —
Every year more than 146,000 Americans are diagnosed with colorectal cancer , the third most common type of cancer in the United States. It also is the third highest cause of cancer death, killing nearly 50,000 people annually, more than who die each year on the nation’s roadways. This cancer affects men and women in nearly equal numbers. Continue
In patients with stage III colon cancer who have undergone complete resection of the primary tumor or for palliative…
Added by Peter Hofland, PhD on January 13, 2011 at 2:30pm —
Researchers at The Children's Hospital of Philadelphia have identified variations in a gene as important contributors to neuroblastoma, the most common solid cancer of early childhood.
The study team, led by researchers at The Children's Hospital of Philadelphia, found that common variants in the LMO1
gene increase the risk of developing an aggressive form of neuroblastoma, and also mark the gene for… Continue
Added by Peter Hofland, PhD on December 1, 2010 at 11:00am —
Ninety percent of children who lived in a house where an adult smoked had evidence of tobacco-related carcinogens in their urine, according to research presented at the Ninth AACR Frontiers in Cancer Prevention Research Conference, held in Philadelphia from November 7-10, 2010. Continue
The average amount of tobacco metabolites in children aged one month to 10 years old was 8 percent of what is found in a smoker, said the lead researcher Janet L. Thomas, Ph.D.,…
Added by Peter Hofland, PhD on November 9, 2010 at 11:00pm —
For the first time, UK scientists have reported direct evidence that taking up smoking results in epigenetic changes associated with the development of cancer. The results were reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.
The link between smoking and cancer has been established for decades, explained Dr Yuk Ting Ma from the Cancer Research UK Institute of Cancer Studies, Birmingham, who presented the… Continue
Added by Peter Hofland, PhD on October 9, 2010 at 5:30am —
Drugs which reverse epigenetic abnormalities are looking very promising in the treatment of some blood cancers and may have a role to play in solid tumors such as lung cancer. These research results are being presented at the 15th Congress of the European Hematology Association (EHA) taking place from June 10 to 13 at the Fira Barcelona Gran Via in Barcelonin, Barcelona, Spain.
In cell biology epigenetics refers to inherited changes in gene expression caused… Continue
Added by Peter Hofland, PhD on June 11, 2010 at 11:30am —
The North Central Cancer Treatment Group (NCCTG), a national clinical research group sponsored by the National Cancer Institute, plans to conduct a Phase II study of brostallicin in combination with cisplatin in patients with metastatic triple-negative breast (mTNBC) cancer. These cancers… Continue
Added by Peter Hofland, PhD on April 27, 2010 at 11:00pm —
The European Medicines Agency (EMEA) Pediatric Committee (PDCO) today released its findings requested that Cell Therapeutics, Inc submit an updated Pediatric Investigation Plan (PIP) for pixantrone following discussions about the preclinical and clinical pixantrone data, including PIX301, and the desire to explore the potential benefits pixantrone may offer to children with hematologic cancer.
Following the request Cell Therapeutics, cexpects to… Continue
Added by Peter Hofland, PhD on April 21, 2010 at 7:00pm —
Seattle -based Cell Therapeutics, Inc, biopharmaceutical company committed to developing an integrated portfolio of oncology products, today announced that its new class of platinum-based anti-tumor compounds, termed bis-platinates, demonstrated a stronger anti-tumor potency and activity compared to currently available platinum-based compounds as well as the ability to overcome cisplatin-resistance in cancer cell… Continue
Added by Peter Hofland, PhD on November 29, 2009 at 11:30pm —
Researchers using the OncoVue® (InterGenetics Inc,655 Research Parkway, Suite 300, Oklahoma City, OK 73104) clinical breast cancer model for assessing genetic risk had much higher accuracy when compared with the more commonly used Gail model, according to data presented at the 31st Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS, December 10 - 14, 2008).
By using a combination of a questionnaire and a saliva test, the OncoVue® model takes into account… Continue
Added by Peter Hofland, PhD on February 2, 2009 at 6:00pm —
Arizona based Translational Genomics Research Institute (TGen), a non-profit organization dedicated to conducting groundbreaking medical research, together with Scottsdale Healthcare, a primary clinical research facility housed in the Virginia G. Piper Cancer Center in Scottsdale and Mayo Clinic, one of only 39 U.S. medical centres that have been named as a National Cancer Institute (NCI) Comprehensive Cancer Center, started testing VTX-2334, a novel Toll-Like Receptor 8 (TLR8) agonists… Continue
Added by Peter Hofland, PhD on December 29, 2008 at 5:00pm —